文献速递中医内科中药与中成药合理使用

中药联合EGFR-TKIs治疗晚期非小细胞肺癌的系统评价与Meta分析

Chinese Herbal Medicine for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Chin Med · 2018-07-12

该系统评价与Meta分析纳入64项随机对照试验共4384例晚期非小细胞肺癌患者,评估中药联合表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)对比单用EGFR-TKIs的疗效与安全性。结果显示联合治疗在无进展生存期、中位生存时间、1年及2年生存率、客观缓解率、卡氏评分、严重毒性概率及CD3+、CD4+T淋巴细胞改善百分比等方面均显著优于单用EGFR-TKIs,但结果需进一步确认。

要点

  • 中药联合EGFR-TKIs在晚期NSCLC中可能改善生存、缓解率与体能状态。
  • 联合治疗可能降低严重毒性概率并改善T淋巴细胞亚群百分比。
  • 上述获益证据来自64项RCT的Meta分析,仍需进一步研究确认。

核心结论

  • 与单用EGFR-TKIs相比,中药联合EGFR-TKIs在晚期非小细胞肺癌患者的生存、缓解率、体能状态、毒性及免疫指标方面显示出潜在获益。

研究设计与样本

  • 系统评价与Meta分析,系统检索后纳入64项随机对照试验,共涉及4384例患者。

主要发现

  • 联合治疗在无进展生存期、中位生存时间、1年生存率、2年生存率、客观缓解率、卡氏评分、严重毒性概率以及CD3+和CD4+T淋巴细胞改善百分比方面均显示有利于联合治疗的显著差异。

临床怎么用

  • 在晚期非小细胞肺癌接受EGFR-TKIs治疗时,可考虑将中药作为辅助治疗以潜在改善临床疗效、耐药与毒性。

局限性

  • 原文指出上述结果仍需进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chinese herbal medicine (CHM) has been widely used in the treatment of advanced non-small-cell lung cancer (NSCLC), but their efficacy and safety remain controversial. We sought to comprehensively aggregate and evaluate the available evidence on the efficacy and safety of the combination treatment with CHM and epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in NSCLC patients. Our exhausted and systematical searching strategy yielded 64 related randomized controlled trials involving 4384 patients. Compared with EGFR-TKIs therapy alone, meta-analysis showed significant differences favoring the combination treatment in progression-free survival ([Formula: see text]), median survival time ([Formula: see text]), one-year survival rate ([Formula: see text]), two-year survival rate ([Formula: see text]), probability of severe toxicities ([Formula: see text]), objective response rate ([Formula: see text]), Karnofsky performance status ([Formula: see text]), and improvement in percentage of CD3[Formula: see text] T lymphocyte ([Formula: see text]) and CD4[Formula: see text] T lymphocyte ([Formula: see text]). Though these results require further confirmation, they are prone to show a potential therapeutic value of CHM in improving the clinical effect, overcoming the drug resistance and toxicities as an adjunctive therapy to EGFR-TKIs.

来源:Am J Chin Med,查看原文。版权归原作者所有。

引用

  1. Zhang XW, Liu W, Jiang HL, et al. Chinese Herbal Medicine for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Am J Chin Med. 2018. PMID: 30001642. doi:10.1142/S0192415X18500490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。